EXACT SCIENCES CORPEXASEarnings & Financial Report
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
Revenue
$850.7M
Gross Profit
$583.9M
Operating Profit
$-25.5M
Net Profit
$-19.6M
Gross Margin
68.6%
Operating Margin
-3.0%
Net Margin
-2.3%
YoY Growth
20.0%
EPS
$-0.10
Financial Flow
EXACT SCIENCES CORP Q3 2025 Financial Summary
EXACT SCIENCES CORP reported revenue of $850.7M (up 20.0% YoY) for Q3 2025, with a net profit of $-19.6M (up 48.8% YoY) (-2.3% margin). Cost of goods sold was $266.8M, operating expenses totaled $609.5M.
Key Financial Metrics
| Total Revenue | $850.7M |
|---|---|
| Net Profit | $-19.6M |
| Gross Margin | 68.6% |
| Operating Margin | -3.0% |
| Report Period | Q3 2025 |
Revenue Breakdown
EXACT SCIENCES CORP Q3 2025 revenue of $850.7M breaks down across 2 segments, led by Screening at $666.2M (78.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Screening | $666.2M | 78.3% |
| Precision Oncology | $184.5M | 21.7% |
EXACT SCIENCES CORP Revenue by Segment — Quarterly Trend
EXACT SCIENCES CORP revenue by segment across the last 4 reported quarters, showing how each business line (such as Screening and Precision Oncology) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Screening | $695.1M | $666.2M | $628.5M | $540.0M |
| Precision Oncology | $183.2M | $184.5M | $182.6M | $166.8M |
EXACT SCIENCES CORP Annual Revenue by Year
EXACT SCIENCES CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.2B).
| Year | Annual Revenue |
|---|---|
| 2025 | $3.2B |
| 2024 | $2.8B |
| 2023 | $2.5B |
| 2022 | $2.1B |
EXACT SCIENCES CORP Quarterly Revenue & Net Profit History
EXACT SCIENCES CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $878.4M | +23.1% | $-86.0M | -9.8% |
| Q3 2025 | $850.7M | +20.0% | $-19.6M | -2.3% |
| Q2 2025 | $811.1M | +16.0% | $-1.2M | -0.1% |
| Q1 2025 | $706.8M | +10.9% | $-101.2M | -14.3% |
| Q4 2024 | $713.4M | +10.3% | $-864.6M | -121.2% |
| Q3 2024 | $708.7M | +12.8% | $-38.2M | -5.4% |
| Q2 2024 | $699.3M | +12.4% | $-15.8M | -2.3% |
| Q1 2024 | $637.5M | +5.8% | $-110.2M | -17.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $637.5M | $699.3M | $708.7M | $713.4M | $706.8M | $811.1M | $850.7M | $878.4M |
| YoY Growth | 5.8% | 12.4% | 12.8% | 10.3% | 10.9% | 16.0% | 20.0% | 23.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.38B | $6.67B | $6.75B | $5.93B | $5.71B | $5.80B | $5.90B | $5.86B |
| Liabilities | $3.24B | $3.48B | $3.54B | $3.53B | $3.31B | $3.33B | $3.40B | $3.46B |
| Equity | $3.13B | $3.19B | $3.21B | $2.40B | $2.40B | $2.47B | $2.50B | $2.40B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-82.3M | $107.1M | $138.7M | $47.1M | $30.8M | $89.0M | $219.9M | $151.7M |